EUCTR2008-001635-34-DE进行中（未招募）不适用
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA0 个研究点目标入组 81 人开始时间: 2009年4月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 81
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects who have been previously diagnosed with CD22-positive, indolent NHL (defined as follicular, marginal zone, or SLL) that has progressed after =2 prior systemic therapies.
- •2. Previous anticancer treatment given must have contained rituximab and chemotherapy, or anti CD20 RIT. Subjects must have exhibited no response or have progressed within 6 months from the completion of the most recent rituximab or rituximab containing therapy or within 12 months of the completion of RIT.
- •3. Measurable disease with at least one lymph node or tumor mass >1.0 cm in the greatest transverse diameter (GTD) and the product of the diameters (PD) =2.25cm2 as measured by CT or MRI.
- •4. Age 18 years or older. (For Japan: Age 20 years or older).
- •5. Eastern Cooperative Oncology Group (ECOG) performance status =2 (corresponds to Karnofsky Performance Status (KPS) =60%).
- •6. Life expectancy =12 weeks.
- •7. Adequate bone marrow function, defined as absolute neutrophil count (ANC) =1.5 x 109/L (=1,500/µL), hemoglobin >9.0 g/dL (>5.6 mmol/L), and platelet count =100 x 109/L (=100,000/µL) with no packed red blood cell (PRBC) or platelet transfusions 2 weeks before the first dose of test article.
- •8. Serum creatinine =2.0 x upper limit of normal (ULN) and urine protein/creatinine ratio =0.5.
- •9. Adequate hepatic function, defined as total bilirubin =1.5 x ULN and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =2.5 x ULN.
- •10. Negative serum pregnancy test within 1 week before first treatment if the subject is a woman of childbearing potential. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
- •11. All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 28 to 56 days after the last dose of test article. A subject is biologically capable of having children if he or she is using contraceptives regardless if his or her sexual partner is sterile or using contraceptives.
- •12. Signed and dated institutional review board (IRB)/independent ethics committee (IEC)-approved informed consent form before any screening procedures are performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 47
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 34
排除标准
- •1. Candidate for potentially curative therapies in the opinion of the investigator.
- •2. History of, or suggestive of, veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).
- •3. Prior allogeneic hematopoietic stem cell transplant (HSCT).
- •4. Autologous HSCT within the last 6 months before receiving test article.
- •5. Prior treatment with inotuzumab ozogamicin.
- •6. Subjects with intolerance to or who have had a severe allergic or anaphylactic reaction to any humanized monoclonal antibodies.
- •7. Major surgery, not related to debulking surgical procedures, within 28 days before the first dose of test article.
- •8. Have received any chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational drugs/devices within 28 days before administration of the first dose of test article. Subjects receiving high doses of corticosteroids must have been tapered to a stable dose at least 14 days before the first dose of inotuzumab ozogamicin
- •9. Pregnant or breastfeeding women.
- •10. Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3b follicular lymphoma.
- •11. Symptomatic central nervous system (CNS) NHL; a lumbar puncture is not required unless CNS involvement with NHL is clinically suspected.
- •12. Current or chronic hepatitis B or hepatitis C infection, or known seropositivity for human immunodeficiency virus (HIV). HIV testing may need to be performed in accordance with local regulations or local practice.
- •13. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition).
- •14. Any evidence of serious active infection (eg, requiring an IV antibiotic or antiviral agent within 4 weeks of test article administration; an active infection requiring oral anti-infective agents within 2 weeks of test article administration; or any other history of deep tissue infection suggestive of underlying immune system dysfunction [fascitis, deep tissue abscess, osteomyelitis, articular septic arthritis] within 12 months of test article administration).
- •15. Concurrent active malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix. Subjects with previous malignancies are eligible provided that they have been disease free for 2 years or more.
- •16. Primary effusion lymphoma.
- •17. Left ventricular ejection fraction (LVEF) that is greater than Grade 1 (NCI CTCAE v3), or the presence of NYHA stage III or IV congestive heart failure.
- •18. Previous myocardial infarction or pulmonary hypertension within the past 6 months.
- •19. Known system vasculitides (eg, Wegener granulomatosis, polyarteritis nodosa, systemic lupus erythematosus), primary or secondary immunodeficiency (eg, severe inflammatory disease).
- •20. History of chronic liver disease (eg, cirrhosis) or suspected alcohol abuse.
- •21. Administration of a live vaccine within 6 weeks of the first dose of test article.
- •22. Any major illness/condition or abnormal laboratory finding that, in the investigator’s judgment, will substantially increase the risk associated with the subject’s participation in the study.
- •23. History of clinically significant ventricular arrhythmia, prolonged QTc, or unexplained syncope.
- •24. Screening QTcF > 470 msec
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Patients with Indolent (slow-growing) Non-Hodgkin Lymphoma (a type of blood cancer) Who Have Failed Treament with Rituximab and Chemotherapy (a drug that prevents the growth of tumor cells) or Radioimmunotherapy(a drug that kills tumor cells with radiation)Indolent Non-Hodgkin's LymphomaMedDRA version: 14.1Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-001635-34-BEWyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA81
进行中（未招募）
不适用
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With IndolentNon-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or RadioimmunotherapyIndolent Non-Hodgkin's LymphomaMedDRA version: 9.1Level: LLTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentEUCTR2008-001635-34-HUWyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research & Development60
进行中（未招募）
不适用
A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With IndolentNon-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or RadioimmunotherapyIndolent Non-Hodgkin's LymphomaMedDRA version: 9.1Level: LLTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentEUCTR2008-001635-34-NLWyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research & Development60
已完成
2 期
Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaLymphomaNCT00868608Pfizer81
进行中（未招募）
1 期
A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic LeukemiaPhiladelphia chromosome (Ph)-negative CD22+ B-cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL)MedDRA version: 20.0 Level: LLT Classification code 10000845 Term: Acute lymphoblastic leukemia System Organ Class: 100000004864EUCTR2016-004942-27-FICentre Hospitalier de Versailles130